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Tripeptidyl peptidase II (TPP2) is a serine peptidase in-
volved in various biological processes, including antigen
processing, cell growth, DNA repair, and neuropeptide
mediated signaling. The underlying mechanisms of how a
peptidase can influence this multitude of processes still
remain unknown. We identified rapid proteomic changes
in neuroblastoma cells following selective TPP2 inhibition
using the known reversible inhibitor butabindide, as well
as a new, more potent, and irreversible peptide phospho-
nate inhibitor. Our data show that TPP2 inhibition indi-
rectly but rapidly decreases the levels of active, di-phos-
phorylated extracellular signal-regulated kinase 1 (ERK1)
and ERK2 in the nucleus, thereby down-regulating signal
transduction downstream of growth factors and mito-
genic stimuli. We conclude that TPP2 mediates many im-
portant cellular functions by controlling ERK1 and ERK2
phosphorylation. For instance, we show that TPP2 inhibi-
tion of neurons in the hippocampus leads to an excessive
strengthening of synapses, indicating that TPP2 activity is
crucial for normal brain function. Molecular & Cellular
Proteomics 14: 10.1074/mcp.M114.043331, 2177–2193,
2015.
Tripeptidyl peptidase II (TPP2) is a ubiquitously expressed,
mainly cytoplasmic, 138kDa protein that forms homopolymer
complexes of 6MDa (1). The N-terminal subtilisin-type ser-
ine peptidase domain becomes activated upon complex for-
mation (2). The C terminus is important for complex formation
but also contains two signature motifs, one of which is a
suspected breast cancer gene 1 carboxy-terminal (BRCT)
domain (1, 3). TPP2 complex assembly in vitro is enhanced by
competitive peptide inhibitors (4). As the name suggests,
TPP2 has exopeptidase activity and cleaves aminoterminal
tripeptides from substrates (5). However, only a small number
of peptide substrates have been identified (6–8). Additionally,
TPP2 possesses a weak endopeptidase activity, of which only
a few substrates, up to 75 amino acids in length, have been
identified by in vitro digests using purified TPP2 (5, 9–11).
In contrast to the low number of polypeptides that have
been established as bona fide TPP2 substrates, a myriad of
important physiological processes and pathologies have been
recognized to be mediated by this protein complex. That
TPP2 is an essential protein is supported by the finding that
homozygous knock down in mice and Caenorhabditis elegans
is lethal (12). TPP2 is involved in antigen processing (13–18),
cell growth, DNA damage repair and carcinogenesis (19–22),
fat metabolism, feeding behavior, and obesity (12, 23). While
the majority of those processes has been linked to TPP2 by
describing individual phenotype and expressional changes of
TPP2 as well as connected individual proteins (24–26), only
antigen processing and feeding behavior have been directly
related to TPP2 peptidase activity by identifying involved pep-
tide substrates (6, 9, 10, 23). TPP2 has been shown to gen-
erate a few specific epitopes via its endopeptidase activity, for
instance, for specific HLA allele mediated peptide presenta-
tion (10, 11, 17, 27). It has been suggested a role of TPP2 in
obesity relies on exopeptidase cleavage of the satiety signal-
ing neuropeptide cholecystokinin-8, which subsequently reg-
ulates feeding behavior (12, 17, 28). The uniform expression of
TPP2 in the brain (29, 30), including regions that are not
involved in the regulation of feeding behavior, suggests a
hitherto general function in neuronal cells. One systematic
study of transcriptomic changes following 10 days of TPP2
knock down in immortalized Burkitt lymphoma cells showed
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an influence of TPP2 on the transcription of genes encoding
proteins involved in signal transduction like ERK2 and JNK
(26). Until now, no systematic evaluation of proteins affected
by TPP2 activity and/or expression has been reported.
As the basis for this study, we determined TPP2-mediated
rapid proteomic changes in human neuroblastoma cells as a
model system for neurons that are induced by the TPP2
inhibitors butabindide and B6, a novel in-house developed,
highly potent, irreversible inhibitor. As indicated by the result-
ing data, we observed that TPP2 inhibition in mouse hip-
pocampal neurons led to a strengthening of synapses, point-
ing toward an involvement of TPP2 in learning and memory.
Additionally, the proteomic data revealed that TPP2 inhibition
changes the expression of proteins that are linked to the
ERK2 function, a connection we found to rely on a rapid
reduction of phosphorylation level and thereby the activity of
ERK1 and ERK2 in the nucleus of neuroblastoma cells. Our
data support the view that TPP2 regulates a major signal
transduction pathway, thereby influencing many cellular pro-
cesses like development, proliferation, carcinogenesis and
DNA-damage response (31–34), and synaptic strengthening
(35, 36), indicating an important role for TPP2 in neuronal fate
and function.
EXPERIMENTAL PROCEDURES
B6 Synthesis—Schematic presentation of synthesis strategy is
shown in Fig. 1A, and a detailed description of the synthesis can be
found in the supplementary file Experimental Procedure.
TPP2 Purification—TPP2 was purified from human red blood cells
as described previously (8), using the reported modifications (37, 38).
The enzyme was frozen in liquid nitrogen and stored at 80 °C.
IC50 Value and TPP2 Irreversibility—For determination of the IC50
value, human TPP2 (hsTPP2) was incubated with butabindide (Tocris
Biosciences, Bristol, UK) or B6 at concentrations between 5 pM and 1
M in 0.1 M potassium phosphate buffer, pH 7.5, containing 12%
glycerol and 2 mM DTT for 15 min at 37 °C before addition of 100 M
H-Ala-Ala-Phe-pNA (AAF-pNA). The change in absorbance at 405 nm
was measured continuously for 45 min (Fig. 1B). For the irreversibility
assay, hsTPP2 was incubated with the inhibitor at 20-fold higher
concentration for 0 min or 30 min at 37 °C, then diluted 20-fold and
added to the 96-well plate. The substrate (AAF-pNA, Bachem, Buben-
dorf, Switzerland) at 100 M was added after an additional 5 min
preincubation at 37 °C. The final concentration during the activity
measurement is indicated (Fig. 1C). Absorbance resulting from pNA
(p-nitroaniline, A 405–410 nm) release due to AAF-pNa cleavage by
hsTPP2 was detected over time. The resulting hsTPP2 activity is
represented by absorbance in time and was normalized to TPP2
activity in absence of inhibitors. The IC50 value was determined using
the tangent equation of the regression function.
TPP2 Activity Assay—neuroblastoma cellline SH-SY5Y cells trans-
duced with shRNA or incubated for 4 h with Dimethyl Sulfoxide
(DMSO), butabindide or B6 (concentrations as indicated in Fig. 2A)
were lysed in 25 M digitonin (Sigma Aldrich, Buchs, Switzerland) in
KMH buffer (110 mM KAc, 2 mM MgAc, and 20 mM Hepes-KOH, pH
7.2). Organotypic hippocampal slices were isolated from P7 mice,
and cultured for 6–13 days in vitro (DIV) in culture medium. After
incubation for 6 h with 1% (v/v) DMSO, 10 or 100 M B6 in slice
culture medium, brain slices were homogenized in PBS containing 25
M digitonin (data not shown). Lysates were incubated for 30 min on
ice and centrifuged for 15 min at 14,000 rpm at 4 °C. 50 M bestatin
(Enzo lifesciences AG, Farmingdale, NY) were added to 5 g protein
from the cell lysates in KMH buffer and incubated for 30 min at 4 °C.
Subsequently, 100 M AAF-AMC (Bachem) was added to a total
volume of 50 l. Degradation of AAF-AMC was analyzed at 37 °C
using the FLUOstar OPTIMA (BMG Labtec, Ortenberg, Germany). The
reaction was incubated for 30 min on ice and centrifuged for 15 min
at 14,000 rpm at 4 °C. The remaining TPP2 activity was determined
using AAF-AMC degradation assay in presence of bestatin. The graph
shows mean relative TPP2 activity normalized to DMSO-treated brain
lysates (n  3, S.D.).
Inhibitor Stability—Stock solutions of 10 mM B6 or butabindide in
DMSO were diluted in PBS, pH 7.2 (cfinal  20 M). An aliquot (200
pmol) was directly applied to LC-MS (0 h). Further aliquots were taken
after 4 and 24 h incubation at 37 °C and analyzed (for results, see Fig.
1D). Before samples were applied to LC-MS (see Florea et al. (39) for
instrument details not listed), acetonitrile (ACN, end v/v 5%) and
formic acid (pHend  3) were added. The column was packed with
BioSphere C18 5-m 120-Å particles from (Nanoseparations, Nieu-
wkoop, the Netherlands). Samples (injection volume 10 l) were sep-
arated in the presence of 0.1% formic acid using a 10 min gradient of
20–35% acetonitrile and 80–65% water on a Surveyor-LCQ system
(Thermo, Waltham, MA) with a flow rate of 1 ml/min. The samples
were analyzed on a LTQ-Orbitrap (Thermo) using the following pa-
rameters: source 3.5 kV and 7 A; capillary 32 V and 275 °C; tube lens
105 V; scan event details: full MS scan with a mass resolution of
30,000 (Fourier Transform Mass Spectrometer (FTMS) pnorm) with
a m/z range 150–1,200; for MS2 and MS3: m/z range 100–2,000,
resolution 15,000, normalized collision energy 35%, activation q 
0.25 and t 30 ms, IsoW 1.0. Resulting raw data were analyzed using
X.calibur software (version 2.0.7 from Thermo Fisher Scientific).
ESI-MS B6 (compound 1) Rt(8.2 min) m/z 550 [3H]
; MS2 550:
465 (100) [3-C4H7NOH]
; MS3 465: 231 (100) [(3-C4H7NO)-
C12H11O3p  H]
, 320 (23) [(3-C4H7NO)-C9H7NOH]
; B6 hydroly-
sis product (compound 3) Rt(6.7 min)m/z: 474 [4H]
;MS2 474: 380
(100) [4-C6H6OH]
; 389 (95) [4- C4H7NOH]
; MS3 380: 298 (100)
[(4-C6H6O)-HPO2-H2OH]
; 213 (33) [(4-C6H6O)-C5H12NPO2-
H2OH]
; 362 (15) [(4-C6H6O)-H2OH]
; MS3 389: 231 (100) [(4-
C4H7NO)-C6H6O3p  H]
; 244 (50) [(4-C4H7NO)-C9H7NOH]
.
ESI-MS Butabindide (compound 2) Rt(1.2 min) m/z 304 [5H]
;
butabindide cyclization product (compound 4) Rt(4.7 min) m/z 231
[6H].
Generation and Validation of the TPP2 Knockdown Cell Line—The
lentiviral shRNA TPP2-specific sequence used was CCGGCCTGAT
CCTTTCAGGT CTGAACTCGA GTTCAGACCT GAAAGGATCA GGT-
TTTTG (Sigma Aldrich, Buchs, Switzerland). The SHC002 scrambled
shRNA construct (Sigma-Aldrich) was used as a negative control. All
shRNA constructs were in the pLKO.1 vector backbone. shRNA-
expressing lentiviral particles were prepared using HEK293T cells and
the virus was transduced into SH-SY5Y cells as described previously
(40). The knock down of TPP2 was confirmed by qPCR (see section
RNA Isolation and Quantitative PCR) on the protein level by Western
blotting, and TPP2 activity was measured using the AAF-AMC TPP2
activity assay (see section TPP2 Activity Assay). The TPP2 shRNA
transduced cell line that was used here showed a decrease in TPP2
mRNA and protein level as well as TPP2 activity of 60–65% com-
pared with a mock shRNA stable cell line as well as wild-type SH-
SY5Y cells (see Supplemental Figs. 2D and 2E). Transductions with
other shRNA sequences did not grow and consequently died, as in
agreement with literature (12).
Transfection—1 g plasmid GFP-ERK2 (kindly provided by P.
Stork, Oregon Health & Science University, Portland, OR) (41) was
transfected into SH-SY5Y cells using Lipofectamine2000 (Invitrogen
Thermo Fisher Scientific Inc., Paisley, UK) using the protocol recom-
mended by the company.
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Cell Culture—SH-SY5Y cells were incubated at 37 °C and 5%CO2.
General culture medium was DMEM high glucose supplemented with
10% FCS, 2 mM L-glutamine, and penicillin/streptomycin (100 U/ml).
For stable isotope labelling with amino acids in cell culture Stable
isotope labeling by amino acids in cell culture (SILAC) experiments,
cells were cultured in DMEM high glucose without K and R (GE
Healthcare, Buckinghamshire, UK) supplemented with 10% dia-
lyzed FCS, 2 mM L-glutamine, penicillin/streptomycin (100 U/ml),
0.8 mM L-lysine either K4Da (H2N(CH2)2(CD2)2CH(NH2)CO2H 
2HCl) or K8Da (H2
15N(13CH2)4
13CH(15NH2)
13CO2H  2HCl), and
0.4 mM L-arginine R6Da (13C6H14N4O2  HCl) or R10Da
(13C6H14
15N4O2  HCl) for 48 h. Amino acid stable isotopes were
purchased from EUR-ISOTOP. Inhibition of TPP2 was performed by
supplementing culture medium with 1 M butabindide or 1 M B6
(1/10,000 (v/v) from 10 mM stock solution dissolved in DMSO) and,
respectively, 1/10,000 (v/v) DMSO and incubating cells for 4 h (in the
case of SILAC, the last 4 h of 48 h labeling), except for concentration
optimization experiments. For experiments under stimulated phos-
phorylation of ERK1 and ERK2, 100 ng/ml of Phorbol-12-myristate
13-acetate (PMA) was added 15 min before harvesting the cells.
Proteome Analysis—Cells were trypsinized. After washing with
PBS, cell pellets were lysed (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1% TritonX-100, complete inhibitor mix (Roche), 100 mM DTT)
and directly incubated at 95 °C for 3 min. Afterward, lysates were
sonicated and centrifuged (15 min, 10,000 rpm). Protein concentra-
tion was determined. Medium heavy labeled lysate (control condition)
was pooled with heavy labeled lysate (TPP2 inhibition or knock down)
to achieve a protein ratio of 1:1. The ethanol-precipitated protein
pellet was dissolved in 6N urea/2N thiourea. After incubation with 55
mM iodoacetamide for 30 min at RT in the dark, proteins were predi-
gested with lysyl-C endopeptidase (WakoChemicals, Richmond, VA)
for 3 h at RT then diluted (5xvol 50 mM ammonium bicarbonate
(ABC))1 and digested with trypsin (Promega, Fitchburg, WI) at RT
overnight. After acidic deactivation of trypsin, peptides were desalted
via C18-Stage-Tip purification. (42) Peptides were separated via SCX-
chromatography using settings adapted from Brunner et al. (43). The
resulting 24 fractions were desalted via C18-Stage-Tip purification
(42), and peptide samples were analyzed on a Surveyor nano-LC
system (Thermo) connected to an LTQ-Orbitrap mass spectrometer
(Thermo). The column was packed with BioSphere C18 5-m 120-Å
particles from Nanoseparations. Instrument settings and measuring
parameters were used as described by Florea et al. (39). Overall, three
biological replicates for each (a) TPP2 knock down to mock shRNA
and (b) TPP2 inhibition by B6/DMSO and four biological replicates for
(c) TPP2 inhibition by butabindide/DMSO were prepared and the
resulting raw data were analyzed by MaxQuant software (version
1.2.2.5) (44, 45) using the Andromeda search algorithm against the
ipi.HUMAN.v3.68 database (both versions from June 2012) in one
analysis. Parameters used for peptide based protein identification
and quantification in MaxQuant: tryptic cleavage, max. two miscleav-
ages; variable modification of methionines by oxidation and of alpha-
aminogroup by acetylation; fixed modification on cysteines by carb-
amidomethylation; special amino acids K and R; multiplicity of 3; no
deisotoping; mass tolerance for precursor ions 20 ppm and for frag-
mented peptides of 0.5 Da; minimum peptide length of six amino
acids; and a max. false discovery rate of 0.01 (peptide and protein
level). The quantification was based on nonmodified peptides and
peptides with variable modifications (razor and unique), low-scoring
versions of peptides were not used; min. ratio count of a replicate was
2. Data from MaxQuant analysis were processed using Perseus soft-
ware version 1.5.0.15 (44). Quantifications (normalized ratio H/M)
were transformed in log2FC. Protein matches from reversed peptide
database, contaminants, and only identified hits were deleted. Pro-
teins quantified in less than three replicates of knock down or both
inhibitors were deleted. P1 values of knock down (n 3), butabindide
(n  4) and B6 (n  4), as well as for all possible combinations of two
of these sample sets, were determined. Additionally, Significance B
value (44) of the median relative quantifications for knock down,
butabindide and B6 was determined (log2FC of each protein toward
Intensity of MH of respective labeled peptides). Only proteins were
included in the protein list for TPP2-induced proteomic changes that
were more than 1.25-fold changed in the same direction in a minimum
of two out of the three screens (two inhibitors and TPP2 knock down),
with significance B and P1 value of p  .05 (for relevant quantifica-
tions). Heat maps (with produced Perseus software version 1.5.0.15)
of those proteins are presented in Fig. 3B; quantification results and
statistical values can be found in Supplemental Table 1 (online). A
schematic presentation of the experimental procedure can be found
in Fig. 3A. A list of proteins significantly changed in only one out of the
three screens (that have been stated (numbers) in the Venn diagram
Fig. 3A) can be found online in Supplemental Table II.
Approximate Protein Half-Life Determination—An aliquot of each
separate SILAC-labeled (48h labeling) cell lysate was taken for deter-
mination of an approximate protein turnover/half-life, prepared and
analyzed the same way (MaxQuant multiplicity 2 instead). The half-
life/turnover of the proteins TPP2 was calculated from SILAC quan-
tifications of aliquots using the Eqs. (Ia) and (Ib) are in Supplementary
Fig.1). For a schematic presentation of experimental procedure and
calculation of the approximate t1/2 (approximate due to expected
minor effects of natural isotope recycling in 48 h of SILAC) for TPP2,
see Supplemental Fig. 1.
Biological Process and Functional Interaction Annotation Analysis
of Proteomic Data—The overlapping proteins influenced by TPP2 as
determined by SILAC (Fig. 3B and online Supplemental Table I) and
functional interactors or linkers were applied to the pathway analysis
tool Cytoscape (version 3.0.2) and overrepresented GO biological
processes that were significantly (false discovery rate and p value
.05) influenced by TPP2 were analyzed using FI Reactome app (46,
47). The results are presented in Table I. Furthermore, with using the
same proteins and selection criteria overrepresented pathways were
determined and are presented online in Supplemental Table III. Func-
tional interactions of proteins increase or decrease by both inhibitors
were also analyzed by Cytoscape (see Supplemental Fig. 3 and
Supplemental Table IV (online)).
Serine Hydrolase Activity Determination—SH-SY5Y cells were lysed
in 25 M digitonin (Sigma Aldrich) in PBS. Protein concentration was
determined via Bradford assay. 20 g protein were incubated for 30 min
on ice in the presence of 2 M ActiveX TAMRA-fluorophosphonate (FP)
Serine hydrolase probe (Thermo Fisher Scientific). As a negative control,
lysate was preincubated with 20 M PMSF (Bachem) (30 min on ice)
before adding the probe. After incubation, 6xSDS-loading buffer was
added and the samples were incubated at 95 °C for 5 min and sepa-
rated via SDS-PAGE (7.5 and 12.5% SDS-PAGels). Gels were scanned
using a Typhoon imager (GE Healthcare, Buckinghamshire, UK) with the
1 The abbreviations used are: ABC, ammonium bicarbonate; Ac,
acetate; AMC, 4-methyl-coumaryl-7-amide; BODIPY, boron-dipyr-
romethene; BRCT-, breast cancer gene 1 carboxy-terminal domain;
CHX, cycloheximide; hsTPP2, human tripeptidyl peptidase II; IC50,
half inhibitory concentration; mEPSC, miniature excitatory postsyn-
aptic current; NEM, N-ethylmaleimide; PEP, posterior error probabil-
ity; pERK, di-phosphorylated extracellular signal-regulated kinase;
PFA, paraformaldehyde; PMA, phorbol-12-myristate 13-acetate;
pNA, p-mitroanilide; PP2A, protein phosphatase 2A; RT, room tem-
perature; SCX, strong cation exchange; SEM, standard error of the
mean; shRNA, short hairpin ribonucleic acid; SILAC, stable isotope
labeling with amino acids in cell culture; TAMRA-FP, carboxytetram-
ethylrhodamine-fluorophosphonate; Var, variance.
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580 BP 30 filter to detect the TAMRA-FP probe and afterward Western
blotted for evaluating the loading control (Fig. 2C and Supplemental
Fig 2A).
Proteasome Activity Determination—SH-SY5Y cells were lysed in
TSDG buffer: 20 mM Tris-HCl, pH 7.6, 10 mM KCl, 2 mM MgCl2, 0.1
mM EDTA, 1 mM DTT, 10% glycerol containing 2 mM ATP via three
freeze–thaw cycles. Protein concentration was determined by Bradford
assay. 20 g protein were incubated for 1 h at 37 °C in the presence of
0.5 M activity-based probe BODIPY-epoxomicin (kindly provided by H.
Overkleeft (Institute of Chemistry, Leiden)) (39). As a negative control,
lysate was preincubated for 30 min on ice with 1 M epoxomicin (Sigma
Aldrich) before adding the activity probe. After incubation, 6x native-
loading buffer was added and samples were separated by native-
PAGETM NuPAGE® Novex® 4–12% Bis-Tris gels (Invitrogen). Gels
were scanned using Typhoon imager (GE Healthcare) with the 580 BP
30 filter to detect the BODIPY-epoxomicin probe and afterwardWestern
blotted for evaluating the loading control (Fig. 2D).
Leucyl-Aminopeptidase Activity Determination—SH-SY5Y cells
were lysed in 25 M digitonin (Sigma Aldrich) in KMH buffer (110 mM
KAc, 2 mM MgAc, 20 mM Hepes-KOH, pH 7.2). Cell lysates were
incubated for 30 min on ice and centrifuged for 15 min at 14,000 rpm
at 4 °C. 100 M L-AMC (Sigma Aldrich) were subsequently added to
5 g protein cell lysate in KMH buffer (total volume: 50 l). Degrada-
tion of L-AMC was analyzed at 37 °C using the FLUOstar OPTIMA
(BMG Labtec.). See Fig. 2E.
Trypan Blue Assay—Cells were trypsinized and centrifuged (1,200
rpm, RT, 3 min). The cell pellet was resolved in cell culture medium.
An aliquot of cell suspension was mixed (1:10) with Trypan blue
solution and applied to a cell counter chamber. After 3 min, cells and
dead cells (Trypan blue positive) were counted (400 cells per ex-
periment counted). See Fig. 2B.
RNA Isolation and Quantitative PCR—RNA from SH-SY5Y cells
was isolated using Trizol (Invitrogen, Waltham, MA) and an overnight
precipitation in isopropanol. Total RNA (1 g) was DNase I treated
and used to generate cDNA (Maxima First Strand cDNA synthesis kit;
Fermentes, Thermo Fisher Scientific) using oligo-dT and random hex-
amer primers. In short, 1 g RNA was mixed with 4 l 5X Reaction
and 2 l Maxima Enzyme Mix, and water was added to a total volume
of 20 l. This solution was incubated at 25 °C for 10 min, followed by
50 °C for 15 min, and the reaction was terminated by heating at 85 °C
for 5 min. The resulting cDNA was diluted 1:20 and served as a
template in real-time qPCR assays. Real-time qPCR (SYBR® Green
PCR Master Mix; Applied Biosystems, Thermo Fisher Scientific) for
target proteins was performed using the forward and reverse primer
pairs as shown below. Expression levels were normalized against a
selection of four reference genes (GAPDH, ACTB, TBP, and YWHAZ)
based on a geNorm analysis (Fig. 4A). The normalization factor was
the geomean of the four reference genes.
Cycloheximide Chase—The stability of the Sry-related HMG box
(SOX)11 protein was assayed by addition of cycloheximide (50 M)
(Sigma Aldrich) to SH-SY5Y cells incubated with either B6 1 M,
butabindide 1 M or 1/10,000 (v/v) DMSO for 4 h. Subsequently, cells
were applied to nuclear-cytoplasmic fractionation and analyzed by
Western blotting (Figs. 4C and 4D). All SOX11-positive bands present
on the Western blot (marked with * in Fig. 4) were quantified, summed
up, and normalized to the respective loading controls. The band at 47
kDa represents SOX11 full-length unmodified protein; the main band
60 kDa is assumed to be posttranslational modified and the bands
below 47 kDa to be cleavage products of the intronless transcription
factor SOX11. Since 2/3 of the three SILAC-quantified SOX11 pep-
tides (Fig. 4D and Supplemental Table VI) are homologous to SOX4
(47.3 kDa) and 1/3 is homologue to SOX12 alias SOX22 (36 kDa) and
since the SOX11 antibody epitope sequence (Fig 4D) shows 94%
identity to SOX4 and 82% identity to SOX12 alias SOX22 (36 kDa), the
SOX11 antibody may also detect SOX4 and SOX12 as the two other
SILAC matches. We cannot exclude that some of the quantified
bands in the SOX11 bands (indicated with stars in Fig. 4) overlap or
are SOX4 or SOX12; however, it is most comparable to the SILAC
quantification. We deliberately marked all Western blots with SOX11.
Nuclear-Cytoplasmic Fractionation—Cells were lysed by incuba-
tion for 15 min on ice in hypotonic buffer (10 mMMgSO4, 37.5 mM KCl,
5 mM Hepes, pH 8.0) containing complete inhibitor mix (Roche, Basel,
Switserland), 50 M PMSF, 1 M epoxomicin, 10 mM NEM, 2 mM
EDTA. Then 0.6% TritonX-100 was added and lysates were syringed
through a 22 gauge needle before lysates were centrifuged (10 min,
10,000 rpm, 4 °C). The supernatant, representing the cytoplasmic
fraction, was transferred into a new tube. The pellet was lysed in
nuclear extraction buffer (100 mM Tris, pH 7.4; 2 mM Na3VO3; 100 mM
NaCl; 1% TritonX-100; 2 mM EDTA; 10% glycerol; 0.1% SDS; 1 mM
NaF; 0.5% deoxycholate; 20 mM Na2P2O7; compete inhibitor mix
(Roche)) by incubating it for 40 min on ice and vortexing every 10 min
for 15 s. Supernatant respective nuclear fraction after centrifugation
(10 min, 10,000 rpm) was transferred into a fresh tube. The protein
concentration of fractions was determined via Bradford, and 20 g of
each fraction was applied to SDS-PAGE.
Western Blotting—Equal protein amounts obtained from the SH-
SY5Y cell lysates were separated on 7.5%, 12.5%, 15% SDS-PAGE
gels or Native gels (Invitrogen). After electrophoresis, proteins were
transferred to a 0.2 m pore size nitrocellulose membrane (GE
Healthcare). Blots were blocked in 5% milk (w/w) in PBS and incu-
bated with the primary antibodies and subsequently with secondary
antibodies from ODYSSEY® Infrared Imaging System anti-goat, anti-
mouse, anti-rabbit generated in donkey with IRDye® 800CW or
680CW (1:10,000; LI-COR Biosciences, Lincoln, NE). The signal was
detected using the Odyssey imaging system (Licor) and quantified
using ImageJ software (version 1.46r Wayne Rasband, NIH, USA).
Antibodies: from Santa Cruz Biotechnology Dalllas, TX: TPP2 (E-
17, sc-15148) goat (WB 1:500), PPP2CA/B (FL-309, sc14020) rabbit
(WB 1:1,000), -actin (I-19, sc-1616) goat (WB 1:2,000), ubiquitin
(P4D1, sc-8017) mouse (WB 1:1,000); from Atlas Antibodies, Stock-
holm, Sweden SOX11 (HPA000536) rabbit (WB 1:750); from Sigma
Aldrich, Cambridge, UK: pERK1/2 (M8159) mouse (WB 1:10,000);
TPP2 (HPA021069) rabbit (ICC 1:50); from abcam: Histone H3 (1791–
100) rabbit (WB 1:3,000), -tubulin (DM1A, ab7291) mouse (WB
1:10,000, ICC 1:200), 2 proteasomal subunit (MCP21, ab22666)
mouse (WB 1:1,000); from Biomol, Plymouth Meeting, PA: RPT1/S7
(PW8825) mouse (WB 1:1,000).
Immunostaining—Cells grown on coverslips were treated with re-
spective conditions then washed with PBS and fixed with 2% para-
formaldehyde (PFA; Electron Microscopy Sciences, Hatfield, PA) in
PBS (20 min, 4 °C). Proteins were denatured with methanol (5 min,
RT), cells permeabilized with 0.1% Triton-X100 in PBS (10 min, RT),
and unspecific binding sides were blocked with 1% BSA in PBS (10
min, RT). Fixed cells were incubated with antibody against TPP2
generated in goat (1:50, Santa Cruz, E-17, sc-15148) for 1 h at room
temperature, washed with PBS, and then incubated for 30 min in the
dark with Cy3-tagged anti-goat generated in donkey (1:500, Jackson,
Bar Harbor, ME). After washing with PBS, coverslips were mounted
with DAPI containing VectaShield® (Vector Laboratories, Inc., Burlin-
game, CA), and staining was investigated using a Leica TCS SP8 X
Confocal Microscope with the software LAS AF Version 2.6.3 (Leica
Microsystems, Wetzlar, Germany).
Quantification of Nuclear Protein via Confocal Microscopy—For
confocal image based nuclear protein quantification, confocal images
(with identical magnification and settings (gain, offset, laser power)
were analyzed using Leica AF software by manually marking the
nuclear area based on the DAPI staining. The mean of the mean gray
values (channel of TPP2 staining) of each nucleus (n  3 biological
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replicates, 14 images per sample with 200 nuclei quantified) was
determined for DMSO, butabindide, and B6 treated cells as well as cells
treated with secondary antibody only. The least named negative control
was seen as background fluorescence and subtracted from quantifica-
tions of DMSO, butabindide, and B6 before the values were normalized
to DMSO (separately for each biological replicate). Exemplar presenta-
tion of quantification method is shown in Supplemental Fig. 6.
Neurite Outgrowth Analysis—To measure neurite outgrowth, SH-
SY5Y cells were plated on a 96-well plate grown in DMEM 10% FCS
and incubated at 37 °C and 5% CO2. The cells were either treated
with B6 1 M, butabindide 1 M, or 1/10,000 DMSO for 4 h. As a
positive control, cells were plated on a 96-well plate coated with
poly-L-lysine and BD MatrigelTM Basement Membrane Matrix (growth
factor induced) (1 mg/ml) and grown for 10 days in 1 M retinoid acid
dissolved in DMEM 0.5% FCS to induce differentiation. Retinoic acid
medium was refreshed on day 3 and 6 after plating. Cells were fixed
with 2% PFA in PBS for 20 min, washed with PBS, and subsequently
permeabilized in 0.1% Triton-X in PBS for 10 min and blocked with
1% BSA in PBS for 20 min. Then, the primary antibody mouse
-tubulin (1:200 in 1% BSA in PBS) was added for 1 h at room
temperature, followed by the secondary antibody Alexa Fluor® 488
chicken anti-mouse (A21200, 1:500, from Invitrogent, Waltham, MA)
for 30 min incubation at room temperature. Neurite outgrowth was
measured using the Cellomics Arrayscan VTI HCS Reader. Filters
used were XF93-FITC for detecting Alexa 488 anti-mouse and XF93-
Hoechst for detecting the Hoechst staining. Predefined mask algo-
rithms were used to measure neurite length. For analysis five (four in
case of retinoic acid) biological replicates, and for each of them, two
technical replicates were used (Figs. 5A and 5B). For each technical
replicate, 40 images were acquired, using a 10x objective.
Electrophysiology—Organotypic hippocampal slices were isolated
from P7 mice and cultured for 6–13 days in vitro (DIV) in culture
medium. Slices were incubated with 1/100 (v/v) DMSO or 100 M B6
in slice culture medium for 6 h. Whole-cell recordings were obtained
with Axopatch-1D amplifiers (Molecular Devices, Sunnyvale, CA) us-
ing 3- to 5-M	 pipettes with an internal solution containing (in mM):
115 cesium methanesulfonate, 20 CsCl, 10 Hepes, 2.5 MgCl2, 4
Na2ATP, 0.4 Na3GTP, 10 sodium phosphocreatine, and 0.6 EGTA, at
pH 7.25. External perfusion consisted of artificial cerebrospinal fluid
containing (in mM): 119 NaCl, 2.5 KCl, 4 CaCl2, 4 MgCl2, 26 NaHCO3,
1 NaH2PO4, and 11 glucose (pH 7.4) and gassed with 5% CO2/95%
O2 at 37 i.o. 27 °C. Miniature excitatory postsynaptic currents minia-
ture Excitatory Postsynaptic Current (MEPSCs) were recorded in the
presence of 1 M tetrodotoxin (Tocris) and 100 M picrotoxin (Sigma
Aldrich). Statistical comparisons (P) were performed on log-trans-
formed data. See Figs. 5C and 5D.
Statistical Analysis—All values were obtained from three independ-
ent repeated experiments and expressed as mean  S.D., if not
stated differently. Statistical comparisons (P) were performed using
nonpaired two-tailed Student’s t test. p  .05 was considered statis-
tically significant.
RESULTS
B6—A New, Potent, Irreversible TPP2 Inhibitor—Butabin-
dide is currently the only commercially available inhibitor that
is specific for TPP2, but its application is influenced by its
reversibility as well as its instability under mimicked physio-
logical conditions (23, 48). We designed and synthesized an
irreversible variant of butabindide using diphenylphosphonate
as a reactive group targeting the serine residue (49) of the
catalytic site of TPP2 (Fig. 1A). The resulting new inhibitor B6
(IC50 0.46 0.01 nM) was found to be almost 60 times more
potent than butabindide in inhibiting TPP2 (IC50  27  7 nM)
as determined by a comparative TPP2 substrate degradation
assay with purified human TPP2 (hsTPP2) (Fig. 1B). The irre-
versibility of B6 was experimentally confirmed; in particular
preincubation of hsTPP2 with B6 prior to dilution significantly
decreased substrate degradation (Fig. 1C) in contrast to the
reversible inhibitor butabindide where no significant effect of
preincubation was observed. As the described, rapid cycliza-
tion of butabindide under mimicked physiological conditions
interferes with TPP2 inhibition (48); the stability of B6 was
comparatively investigated using the same experimental ap-
proach. No respective cyclization product of B6 was de-
tected, likely due to steric hindrance of the bulky phenyl
groups. Instead, hydrolysis of the B6 “warhead” was ob-
served (Fig. 1D), which is expected to interfere with passive
transport through the plasma membrane due to its negatively
charged group at physiological pH. However, this instability
has low impact on cellular short time-frame applications of B6
as shown by the data presented below and is probably ex-
plained by two observations: first, the hydrophobicity of B6,
suggesting higher membrane permeability and thereby rapid
access to its target. Second, the half-life of TPP2 was found
to be 49  5 h in SH-SY5Y cells (Supplemental Fig. 1), which
combined with the fact that B6 is an irreversible binder implies
a long-term inhibitory effect.
B6 Is a Specific, Nontoxic TPP2 Inhibitor—Prior to applying
the new TPP2 inhibitor to screen for proteomic changes in
SH-SY5Y neuroblastoma cells, the concentration of B6 was
optimized and several possible side and adaptive effects were
investigated. Incubating cells for 4 h with different concentra-
tions of B6 followed by a TPP2 activity assay revealed that 1
M B6 is sufficient to inhibit TPP2 activity (Fig. 2A). Moreover,
under this optimized condition, we did not observe an effect
of B6 on cell death neither when performing a trypan blue
assay (Fig. 2B) nor during time-lapse microscopy recordings
(data not shown). To investigate nonspecific and cell adaptive
effects of B6, lysates of TPP2-inhibited and control noninhib-
ited cells were incubated with activity-based probes for serine
hydrolases and the proteasome, as well as a fluorogenic
substrate for leucyl-aminopeptidases to determine the re-
spective peptidase activities. Besides TPP2, no significant
inhibition of the tested peptidases was detected (Figs. 2C-2E
and Supplemental Fig. 2A). Additionally, we did not observe
significant changes in proteasome levels or proteasome com-
plex formation (Fig. 2D). Interestingly, native gel electropho-
resis indicated that there were major changes in TPP2 com-
plex assembly and/or complex stability in presence of B6 and
minor changes in presence of butabindide (Fig. 2F). This
observation is consistent with described induction of TPP2
complex assembly of TPP2 monomers in vitro in presence of
butabindide (4). Examining TPP2 intracellular localization via
Western blotting of cytoplasmic and nuclear fractionation re-
vealed a mainly cytoplasmic localization of TPP2 in presence
as well as in absence of inhibitor (Supplemental Fig. 2B).
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FIG. 1. B6—A new irreversible TPP2 inhibitor- synthesis, structure, IC50 value, irreversibility, and stability. (A) Schematic synthesis
strategy of B6. Detailed description of B6 synthesis and intermediate products can be found in the supplementary experimental procedure.
Structure of B6 (compound 1) is marked in red. (B) IC50 value of B6 for inhibiting human TPP2 (hTPP2) in vitro. Different concentrations of B6
(red) and in parallel butabindide (blue) were incubated in vitrowith purified hTPP2. The activity was determined via the TPP2 substrate AAF-pNA
and measured as time-dependent fluorescence of free pNA (a.u./min). An average line is shown. A schematic experimental setup is presented
below the graph. Activity relative to noninhibited TPP2 in percentage is plotted against inhibitor concentration (n  3, S.D.). IC50, as
determined by the tangent equation of the regression function for B6 (red) and as reference butabindide (blue) are indicated. (C) Binding of B6
to TPP2 is irreversible compared with butabindide. Different concentrations of B6 (red curves, left side) and in parallel butabindide (blue curve,
right side) were applied to purified human TPP2 and either preincubated (30 min, dashed line) and then diluted 1/20 (v/v) or directly diluted (solid
curve). The activity was determined via the TPP2 substrate AAF-pNA and measured as time-dependent fluorescence of free pNA (a.u./min).
A schematic experimental setup is presented below the graph. Activity relative to noninhibited TPP2 in percentage (n  3, S.D.) is plotted
against final inhibitor concentration after dilution. (D) Stability of B6 under mimicked physiological conditions (310 K, in PBS). Stock solutions
of B6 or butabindide (10 mM in DMSO) were diluted in PBS, pH 7.2 (cfinal  20 M), an aliquot (200 pmol) was directly(0 h), after 4 h, and after
24 h incubation at 310 K applied to LC-MS. Graph shows signal intensity (MS) of B6 ([1H] m/z 550) and butabindide ([3H] m/z 304)
normalized to 0 h value (n  3, S.D.). d.I and d.II represent the chemical reactions of B6 and butabindide as observed under mimicked
physiological conditions and determined by identification of the products using mass spectrometry.
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FIG. 2. B6 specificity and effects in cellular application. (A) Optimum concentration to inhibit TPP2 is 1 M B6. SH-SY5Y cells were
incubated for 4 h with different concentrations of B6, butabindide or respective amounts of the inhibitor solvent DMSO. TPP2 activity in cell
lysates was determined by an AAF-AMC degradation assay (in presence of bestatin). Graph: mean TPP2 activity normalized to nontreated cells
(n  3, S.D.). (B)–(F) Effects of 4 h 1 M TPP2 inhibition and knock down in SH-SY5Y cells. (B) No effect of B6 on cell death. Mean amount
of trypan blue positive cells normalized to DMSO control (n  3, S.D.) (C) No significant change of serine hydrolases activity by B6.
SDS-PAGE of cell lysates (SH-SY5Y 4 h treated with DMSO or TPP2 inhibitors B6/butabindide) incubated with TAMRA-FP serine hydrolase
activity based probe (negative control lysate pretreated with 100 M PMSF). Representative 12.5% SDS-PAGels (additional 7.5% SDS-PAGels
see Supplemental Fig. 2A): serine hydrolase activity (TAMRA signal), -actin, and TPP2 level (WB) and respective plotted profiles of TAMRA
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Immunocytochemistry showed the formation of cytoplasmic
TPP2 accumulations in presence of B6 and to a minor degree
by butabindide (Fig. 2F and Supplemental Fig. 2C). These
accumulations of TPP2 are consistent with an inhibitor-in-
duced TPP2 complex assembly or complex stabilization.
Proteomic Changes by TPP2 Inhibition and Knock
Down—In order to identify the TPP2 client pool. we applied
stable isotope labelling with amino acids in cell culture
(SILAC) to three independent proteomic screens (for experi-
mental setup, see Fig. 3A), the first comparing the effect of B6
signal normalized to -actin. Graph: pool of DMSO and nontreated cells (black S.D.); butabindide (blue) and B6 (red) treated cells (n  2,
mean  S.D.). (D) No significant change in proteasome level, activity or complex formation. (D.I) Proteasome activity and complex formation.
Bar graph represents mean normalized proteasome activity (sum band 1–3: BODIPY/2 WB signal) (n  3, S.D.) as quantified from
native-PAGE. Below the graph representative native PAGE (4–12% gradient gels) shows proteasome activity (BODIPY signal, negative control
epoxomicin treatment previous to activity probe application) and respective Western blot (WB) shows 2 (20S proteasome) and RPT1 (19S
proteasome activator) (1) indicates 30S-, (2) PA28–20S-19S- and 20–19S-, (3) PA28–20S- and 20S-proteasome complexes. (D.II) proteasome
level. Bar graph represents mean normalized proteasome level (2/-actin) (n  3, S.D.) as quantified from SDS-PAGE. Representative
Western blot showing 2, TPP2, and -actin level is presented below the graph (E) No significant effect of B6 leucyl-aminopeptidases. Relative
change of L-AMC degradation measured in cell lysates of B6 and butabindide treated cells normalized to DMSO control (n  3, S.D.,
n.s.  nonsignificant p  .05). (F) B6 influences TPP2 complex assembly/stability and localization. (F.I) Representative confocal pictures of
TPP2 immunostain in greyscale and indicated green in overlay with DAPI. Arrows mark cytoplasmic accumulations of TPP2 in presence of both
TPP2 inhibitors. White scale bar represents 10 m. Negative means represents background stain of the secondary antibody and autofluo-
rescence of the cells. Picture contrast for all pictures has been adjusted equally via Adobe Photoshop. (F.II) Representative Western blot of
native PAGE stained with TPP2 antibody and as loading control 2. Stars (red and blue) indicate shifts toward lower percentage (bulkier
complexes) for butabindide and B6. Black stars indicate small complex or monomeric form of TPP2 that is only present in noninhibited cell
lysates. TPP2 shRNA (60% knock down) serves as control for the staining.
FIG. 3. SILAC approach and resulting proteins affected by TPP2 inhibition and/or knock down. (A) Schematic presentation of
experimental setup to determine relative proteomic changes. Venn diagrams represents proteins reproducible quantified (P1 and significance
B(Log2FC versus Intensity); p  .05) that are minimum 1.25-fold (inhibitors) or 1.5-fold (knock down) increased (upper Venn diagram) or
decreased (lower Venn diagram). For details of quantification see online Supplemental Table I for the overlapping proteins and online
Supplemental Table II for the proteins significantly changed by only one condition. (B) Heat maps of median Log2FC of B6, butabindide and
TPP2 knock down representing targets (first gene name of MaxQuant hit list) showing the same change in minimum two out of three conditions
(quantification details and protein names see Supplemental Table I).
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(4 h, 1 M) to the inhibitor solvent DMSO, the second com-
paring butabindide (4 h, 1 M) to DMSO, and the third repre-
senting genetic loss of TPP2 by comparing stable lines ex-
pressing TPP2 shRNA (65% silencing, see Supplemental
Fig. 3) with mock shRNA. Consistent with literature (12, 50), it
needs to be mentioned that a higher knock down led to
growth arrest and cell death. As a filtering criterion, we only
considered proteins that were reproducibly (P1, p .05) more
than 1.25-fold (significance B, Intensity versus log2FC, p 
.05) (44) increased or decreased as being influenced by TPP2
if they were changed in the same direction in at least two out
of the three screens. Heat maps of the quantification of the
proteins that fit the above mentioned criteria are shown in Fig
3B (for extended quantification results, see Supplemental Ta-
ble I online). In total, 37 proteins were detected as increased;
12 as decreased by either both inhibitors, one inhibitor, and
TPP2 knock down; or all three conditions when compared
with the respective controls. To determine how TPP2 influ-
ences the individual expression levels of these proteins, we
selected five of these proteins (PIK3C2A, MAP2, COL6A1,
SOX11, UBL5) for transcriptional analysis by qPCR (Fig. 4A).
Only SOX11 showed an increase of mRNA level after TPP2
inhibition with butabindide but not with B6. The transcription
of the other four genes were not significantly influenced by
TPP2 inhibition, while COL6A1 and MAP2 showed an in-
crease upon TPP2 stable knock down. The moderate increase
in protein level of SOX11 upon TPP2 inhibition could be con-
firmed by Western blot analysis using a polyclonal antibody that
was raised against an epitope covering all three quantified pep-
tides from the SILAC screen (Figs. 4B-4D). The impact of TPP2
inhibition on SOX11 stability was investigated as an example
since the half-life time of SOX11 and SOX family transcription
factors is below 2 h (51, 52) and thereby smaller than the TPP2
inhibition time period. In the presence of the protein synthesis
FIG. 4. (A) Only SOX11 mRNA is increased by 4 h TPP2 inhibition with butabindide but not with B6. Mean relative change in mRNA level
(qPCR, n  3, S.D.) of B6/DMSO; butabindide/DMSO; TPP2/mock shRNA stable cell lines. (B) and (C) SOX11 protein level is increased by
4 h TPP2 inhibition. (B) Bar diagram shows SOX11 protein level (normalized to DMSO control). SILAC quantifications (median, n  3, S.D.),
WB quantification (mean of summed bands marked with stars, n  6, S.D., WB see Supplemental Fig. 4). (* indicates .05p  .01; ** p 
.01). (C) Representative Western blots of SOX11 total lysate using an antibody targeting the region where all three SILAC-based quantified
peptides are located (see (D)). Stars indicate quantified bands that were summed up. 47 kDa represents SOX11 full length; the other bands
are assumed to be posttranslational modifications (47 kDa) and cleavage products (47 kDa). (D) Localization of SOX11 peptides as
quantified by SILAC and SOX11 antibody binding specificity upper row shows: SILAC-quantified peptides (1–3 green) located in the HMG
DNA-binding domain (amino acid 49–117) of SOX11. The middle row shows the amino acid sequence and position in SOX1. The lower row
represents the epitope used to generate the SOX11 antibody (Atlas Antibodies). (E) and (F) Increased SOX11 protein level is not a result of
increased protein stability. (E) Representative WB of TPP2-inhibitor-treated cells in absence and presence of the protein synthesis inhibitor
cycloheximide (CHX). (F) Mean relative changes (WB quantifications of summed bands marked with stars, n 5,S.D., WBs see Supplemental
Fig. 4) of protein level in absence and in presence of the protein synthesis inhibitor CHX.
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inhibitor cycloheximide, no significant stabilization of SOX11
was observed (Figs. 4E and 4F and Supplemental Fig. 4), sug-
gesting that TPP2 inhibition did not increase SOX11 expression
by altering its degradation but by increasing its translation and
in case of butabindide its transcription.
TPP2 Controls Neurite Outgrowth and Synaptic Plastici-
ty—To further study the cellular response to TPP2 inhibition,
we analyzed overrepresented biological processes (Table I)
and pathways (Supplemental Table III) in the overlapping
changed proteins as determined by SILAC (Fig. 3). Neuron
differentiation, proliferation, cell differentiation and develop-
ment, growth factor signaling, learning, DNA damage re-
sponse, and phosphorylation (Table I) were the main overrep-
resented biological processes (26, 50, 53). Importantly, the
involvement of TPP2 in neuron differentiation and in learning
has not been described before, probably mediated by its
influence on the transcription factor SOX11 (54–56). Addition-
ally, pathways connected to neuron differentiation like NGF
signaling, neural cell adhesion molecule signaling for neurite
out-growth, PI3K-Akt signaling, and pathways connected to
learning like long-term potentiation and glutamate receptor
pathways were found to be significantly affected (Supplemen-
tal Table III). In order to specify these indicated effects, we first
determined the length of neurites in SH-SY5Y cells as an
indicator for neuron differentiation using a Cellomics Array-
scan. Compared with the negative control condition (DMSO),
a significant increase in the length of neurites was observed
following 4 h of TPP2 inhibition (Figs. 5A and 5B). We consider
this increase in neurite length as biologically relevant as it
increased after only 4 h cellular treatment with butabindide
TABLE I
GO biological pathways (FDR0.05, p  .05) of overlapping increased & decreased proteins between different SILAC screens (listed in
Fig. 3). Gene symbols represent proteins increased or decreased by TPP2 inhibition as well as functional interactors (linker proteins, see
Supplemental Fig. 3)
GO biological process (BP)
Proteins
in BP
Proteins
changed
p value FDR Including linker proteins
Positive regulation of
transcription from RNA
polymerase II promoter
636 15 0.0E00 5.0E-03 MYOD1,CTNNB1,MAZ,SOX11,NME2,EP300,JUN,
MAVS,SOX4,HAND2,POU3F3,TAF1,SREBF2,
HDAC2,SETD3
Noradrenergic neuron
differentiation
5 3 0.0E00 2.5E-03 SOX11,SOX4,HAND2
Negative regulation of cardiac
muscle cell proliferation
7 3 0.0E00 4.7E-03 CXADR,RBP4,HDAC2
Glood coagulation 384 10 1.0E-04 2.3E-02 GNA11,CXADR,KIF2B,PRKAR2B,PRKACA,MAPK1,
JMJD1C,HDAC2,FYN,PLCG2
Heart development 128 6 1.0E-04 2.2E-02 GNA11,CXADR,EP300,RBP4,SOX4, HAND2
Sympathetic nervous system
development
16 3 1.0E-04 1.9E-02 SOX11,SOX4,HAND2
Fibroblast growth factor receptor
signaling pathway
131 6 1.0E-04 2.0E-02 PRKAR2B,SPRY2,PRKACA,MAPK1,PPP2CA,FYN
Glial cell proliferation 3 2 2.0E-04 1.9E-02 SOX11,SOX4
Glial cell development 3 2 2.0E-04 1.9E-02 SOX11,SOX4
Epidermal growth factor receptor
signaling pathway
148 6 3.0E-04 3.0E-02 PRKAR2B,SPRY2,PRKACA,PIK3C2A,
MAPK1,FYN
Cardiac ventricle formation 4 2 3.0E-04 2.6E-02 SOX11,SOX4
Neuroepithelial cell differentiation 4 2 3.0E-04 2.6E-02 SOX11,SOX4
Regulation of secondary heart
field cardioblast proliferation
4 2 3.0E-04 2.6E-02 CTNNB1,HAND2
UTP biosynthetic process 6 2 6.0E-04 4.4E-02 NME4,NME2
GTP biosynthetic process 6 2 6.0E-04 4.4E-02 NME4,NME2
Peptidyl-threonine
phosphorylation
29 3 7.0E-04 4.6E-02 MAPK1,TAF1,MAP2
Learning 30 3 8.0E-04 4.9E-02 PRKAR2B,JUN,FYN
DNA damage response,
detection of DNA damage
7 2 8.0E-04 4.6E-02 MRPS9,SOX4
CTP biosynthetic process 7 2 8.0E-04 4.6E-02 NME4,NME2
Positive regulation of
proteasomal ubiquitin-depend-
ent protein catabolic process
32 3 1.0E-03 4.8E-02 TAF1,VCP,CSNK1E
Protein heterotrimerization 8 2 1.1E-03 4.9E-02 PPP2CA,COL6A1
Neural tube formation 8 2 1.1E-03 4.9E-02 SOX11,SOX4
Positive regulation of
transcription, DNA-dependent
436 9 1.1E-03 4.8E-02 SOX11,MAPK1,JUN,SOX4,HAND2,
POU3F3,HDAC2,TCF12,SETD3
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20% and with B6 even 37% of that of the positive control
cells cultured for 10 days in the presence of retinoic acid, a
commonly used method to induce neurite outgrowth (57, 58).
Second, we examined the influence of TPP2 on neuronal
communication. Neurons communicate with each other
through synapses, and synaptic plasticity underlies learning
and memory formation (59, 60). The effect of TPP2 inhibition
on synaptic strength was investigated by recording miniature
excitatory postsynaptic currents (mEPSC) from CA1 neurons
in mouse organotypic hippocampal slices that were incubated
with either B6 or DMSO as a control. No change in mEPSC
frequency was observed, indicating that TPP2 does not affect
presynaptic vesicle release or the number of functional syn-
apses. A significant increase in mEPSC amplitude was
observed after inhibition of TPP2 with B6, indicating that
synapses were strengthened through an increase of -ami-
no-3-hydroxy-5-methyl-4-isoxazolepropionic acid recep-
tor-type glutamate receptors (61) at the postsynaptic mem-
brane (Figs. 5C and 5D).
TPP2 Inhibition Reduces Nuclear pERK1 and pERK2, the
Linker to Most SILAC Targets—A functional interaction anal-
ysis (46, 47) identified mitogen-activated protein kinase
(MAPK1) alias extracellular signal-regulated kinase 2 (ERK2)
to be the protein functionally linked to most of the proteins
that were expressionally affected already after 4 h by both
TPP2 inhibitors (Supplemental Fig. 3, Supplemental Table IV).
With the evidence of a rapid influence on ERK2 signal trans-
duction pathway, we investigated further on these early
changes. Both TPP2 inhibitors had no effect on the protein
level of ERK2 as determined by SILAC (Fig. 6A). The activity of
ERK2 and its interaction partner ERK1 is regulated by phos-
phorylation, which is induced by signal transduction down-
stream of growth factor receptors, like the neuronal or epider-
mal growth factor receptors. The dual phosphorylation of
ERK2, at T185 and Y187, and ERK1, at T202 and Y204,
results in their interaction and translocation into the nucleus
where they activate transcription of several genes (62–65).
Based on the observation that TPP2 inhibition influences
phosphorylation as well as expression of phosphatases and
kinases (Table I and Supplemental Table I), the effect of TPP2
inhibition on active, di-phosphorylated ERK1 and ERK2
(pERK1 and pERK2) levels in the nucleus and cytoplasm of
SH-SY5Y cells was investigated. While no significant changes
in the cytoplasm were observed (Supplemental Figs. 6B and
6C), a significant decrease in active pERK2 and pERK1 in the
nucleus was observed after 4 h of TPP2 inhibition (Fig. 6B).
Determining the ratio of pERK2/ERK2 reveals specifically a
decrease of ERK2 phosphorylation in presence of B6 in the
nucleus while the cytoplasmic phosphorylation level remained
unchanged (Figs. 6C and 6D). A comparable decrease was
FIG. 5. (A) and (B) Inhibition of TPP2 induces neurite outgrowth. (A) Graph shows mean total neurite length/cell  S.D. (n  6) of SH-SY5Y
cells treated for 4 h with 1 M butabindide, 1 M B6 or DMSO, and as positive control SH-SY5Y cells that have been treated for 10 days with
retinoic acid, as determined by Cellomics Arrayscan of -tubulin immunostained cells. (B) Representative pictures (one out of 40 for each
biological replicate) of B6 and DMSO treated cells fixed and stained for -tubulin with respective masks of the Cellomics data analysis. (C) and
(D) TPP2 inhibition by B6 induces an increase in mESPC amplitude in CA1 neurons in mice organotypic hippocampal slices. Brain slices were
incubated for 6 h with 1/100 DMSO or 100 M B6 (optimized B6 concentration showing complete inhibition). mEPSCs were recorded in
presence of tetrodotoxin and picrotoxin. (C) Mean frequency (left graph) and amplitude (right graph)  S.E. (DMSO: n  28; B6 n  26). (D)
Representative mEPSC recording. (nonsignificant (n.s): p  .05; significant: * .05p  .01, *** p  .001, ***** p  .00001).
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also visible when stimulating ERK1 and ERK2 phosphoryla-
tion with PMA (15 min), an activator of protein kinase C
upstream of the ERK2 signaling cascade (Figs. 6C and 6D,
and Fig. 6E confocal images). Together, our data reveal a
substantial and rapid influence of TPP2 on ERK2-mediated
signal transduction. Consistent with our Western blot data,
TPP2 inhibition in GFP-ERK2 overexpressing SH-SY5Y cells
did not induce an obvious recruitment of GFP-ERK2 to the
induced local immunostained accumulations of TPP2 (Sup-
plemental Fig. 5). Although a direct interaction of both pro-
teins cannot be excluded yet, TPP2 has no described kinase
or phosphatase activity (3), indicating the involvement of a
nuclear phosphatase or kinase as a mediator. One phospha-
tase that has been described to dephosphorylate nuclear
pERK2 is protein phosphatase 2A (PP2A) (32, 66, 67). Inter-
estingly, one regulatory subunit of PP2A was increased in the
proteomic screen, PPP2R5C (alias KIAA0044 see Fig. 3 and
Supplemental Table I). Additionally, we found an increase of
PP2A catalytic subunits on the Western blot (Figs. 7A and 7B).
However, we did not observe an increase of PP2A catalytic
subunits in the nucleus upon TPP2 inhibition (Figs. 7C-7E and
Supplemental Fig. 6), indicating that PP2A is not affecting
FIG. 6. (A) TPP2 inhibition does not affect ERK2 cellular protein level. Median relative ERK2 protein level normalized to DMSO treated
cells as determined by SILAC (n  4 biological replicates, S.D. (butabindide n  3, B6 n  4 quantified replicates). (B) TPP2 inhibition
decreases levels of nuclear, active phosphorylated ERK1 and ERK2. Bar diagram: Mean nuclear di-phosphorylated ERK2 (T185 & Y187,
pERK2) and ERK1 (T202 and Y204, pERK1) protein level normalized to histone H3 loading control relative to DMSO control treated cells
as determined by quantification of Western blot signals (n  4, S.D., all Western blots are presented in Supplemental Fig. 5, one
representative Western blot is shown in the right panel Fig. 6C). (C)–(E) TPP2 inhibition decreases phosphorylation level (active form) of
nuclear ERK1 and ERK2 even when stimulating their phosphorylation with phorbol-12-myristate 13-acetate (PMA). (C) Representative
Western blots of nuclear-cytoplasmic (cytopl.)-fractionation from DMSO and TPP2-inhibitor-treated cells without (left panel) and with
15min PMA treatment that were stained for pERK2 and pERK1, ERK2 and ERK1, and the loading controls -tubulin and histone H3. (D)
Mean phosphorylation level of ERK1 and ERK2 in nucleus and cytoplasm. Di-phosphorylated ERK2 (T185 & Y187, pERK2) to total ERK2
and di-phosphorylated ERK1 (T202 and Y204, pERK1) to total ERK1 protein level relative to DMSO-control-treated cells as determined by
quantification of Western blot signals (n  4 biological replicates, S.D., Western blots used for quantification are shown in Fig. 6C and
Supplemental Figs. 5C and 5D). (E) Representative confocal images of PMA-treated cells inhibited with B6 or treated with DMSO as control
that were immunostained for pERK1 and pERK2 (one antibody recognizing both, first column gray, second column (overlay) green) and
DAPI (blue in overlay second column). White bar represents 50 m.
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nuclear phosphorylation of ERK1 and 2 via an up-regulation of
total nuclear PP2A catalytic activity.
DISCUSSION
TPP2 influences numerous important cellular processes
(12, 21, 28, 68), but the underlying mechanisms remain un-
known. In order to elucidate details of its cellular function and
identify proteins that are rapidly influenced by TPP2, we per-
formed a comprehensive proteomic analysis. We determined
proteomic changes following the application of B6, a newly
developed, specific, irreversible TPP2 inhibitor, in parallel with
the commercially available TPP2 inhibitor butabindide (23)
and compared the data with the proteomic effects induced by
stable TPP2 knock down as a reference. To rule out potential
FIG. 7. (A) and (B) TPP2 inhibition increases total cellular protein phosphatase 2A (PP2A) level. Bar diagram shows mean quantification results
of Western blots of cell lysates stained for PPP2CA/B, the PP2A 36 kDa catalytic subunits, normalized to -actin relative to DMSO-control-
treated cells. (lysis: PBS/digitonin; n  5 biological replicates S.D., one representative blot is shown in 7B, the other four in Supplemental
Fig. 6A; significance: * .05p  .01) (B) Representative Western blot used for quantification of total cellular PPP2CA/B level. (C)–(E) No change
in nuclear phosphatase 2A (PP2A) level. (C) Representative Western blot of nuclear-cytoplasmic (cytopl.)-fractionation stained PPP2CA/B
catalytic subunits and the loading controls -tubulin and histone H3. (Additional Western blots of three further replicates and quantification
results are presented in Supplemental Figs. 6B-D) Western blots including quantification is shown in Supplemental Fig. 6) (D) Representative
confocal images of cells inhibited with B6 or treated with DMSO as control that were immunostained for PPP2CA/B, the catalytic subunit of
PP2A (first column gray, second column (overlay) green) and DAPI (blue in overlay second column). Negative immunostain is of cells (second
antibody only) is shown in gray in the third column and in green in the overlay with DAPI (fourth column). White bar represents 50 m. All
pictures have been taken with the same confocal settings (laser power, gain, offset, and for presentation purposes have been processed with
Adobe Photoshop with the same settings (contrast, brightness). (E) Graph: mean nuclear PPP2CA/B protein level as determined by confocal
microscopy (n  3 biological replicates S.D., n  200 cells/condition, images/experiment n  3–8). Mean gray value of the whole nuclear
area (as marked by DAPI) was determined after subtracting the background (negative immunostain nuclear mean gray value) and normalizing
to DMSO nuclear PPP2CA/B signal. All images used for one experiment were taken with the same confocal settings (laser power, gain, offset).
An exemplary quantification is presented in Supplemental Fig. 6D).
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false negatives and positives resulting from unknown nonspe-
cific effects of inhibitors or their metabolites, only proteins that
were changed in the same way in at least two out of these
three conditions were defined as being influenced by TPP2. In
general, TPP2 can affect protein expression either directly or
indirectly. A direct consequence of inhibition is expressional
changes of TPP2 substrates. However, expressional changes
of TPP2 interaction partners can also be suggested since
both inhibitors alter TPP2 complex assembly and/or stability
as well as localization. This may cause a shielding or exposure
of domains, for instance the C-terminal BRCT-domain, that
might interfere with a potential protein-stabilizing or destabi-
lizing interaction of TPP2 (3, 19, 24, 69). TPP2 inhibition can
also change protein expression indirectly via mediator pro-
teins. This secondary effect can occur at the transcriptional
level or by translational changes, as observed for the tran-
scription factor SOX11 (Fig. 4). Alternatively, an indirect
change of protein stability can result from altered expression
of peptidases and other enzymes, which could not be seen as
an effect of TPP2 inhibition.
Analyzing the connections between the proteins that were
rapidly changed by TPP2 inhibition revealed ERK2 as a key
functional protein hub. Most importantly, we showed that
TPP2 inhibition rapidly reduced active, di-phosphorylated
ERK1 (pERK1) and ERK2 (pERK2) in the nucleus without
affecting their total nuclear and cytoplasmic protein level (Fig.
6) even in the presence of PMA as a stimulator of ERK1 and
ERK2 phosphorylation. This indicates a down-regulation of
ERK1- and ERK2-mediated signal transduction via their phos-
phorylation level, suggesting that TPP2 may regulate the
ERK2 signal transduction pathway, which is induced by
growth factors and mitogenic stimuli and controls transcrip-
tion of several genes involved in processes like cell cycle, cell
growth, proliferation, or angiogenesis (62). An influence on
the transcription of genes of the MAPK pathways including
ERK2 after 10 days TPP2 knock down in Burkitt lymphoma
cells has been observed before (24, 26). However, uncov-
ering a rapid regulating influence of TPP2 inhibition on
nuclear phosphorylation level of ERK1 and ERK2 represents
a step forward in understanding the observed cellular func-
tions of TPP2. In the presence of TPP2 inhibitors, overex-
pressed GFP-ERK2 did not show translocation like a re-
cruitment to the observed TPP2 accumulations. However, a
direct probably TPP2 complex structure dependent interac-
tion cannot be excluded yet.
Since TPP2 possesses no described kinase or phospha-
tase activity (3), it is most likely that TPP2 affects phosphor-
ylation of nuclear ERK1 and 2 indirectly by promoting a nu-
clear phosphatase activity pERK1 and pERK2 (Fig. 8). Protein
phosphatase 2A (PP2A) complexes are known to dephospho-
rylate pERK1 and pERK2 in the nucleus. An increase of the
mainly nuclear PP2A regulatory gamma subunit (KIAA0044)
by SILAC and the catalytic subunits PPP2CA/B on Western
blotting was observed after 4 h of TPP2 inhibition (32, 66, 67,
70) (Figs. 3 and 7A and 7B). Since the nuclear PP2A catalytic
subunit levels appeared to be not increased (Figs. 7B-D), the
down-regulation of ERK2 activity in the nucleus is not evoked
by a general up-regulation of PP2A catalytic activity. How-
ever, a shift of the activity of nuclear PP2A complexes with
target specific regulatory subunits, like KIAA0044 that has
been described to target ERK, cannot be excluded, yet
(71, 72).
The regulation of ERK1 and ERK2 phosphorylation by TPP2
can be connected to a number of biological processes influ-
enced by TPP2. Our proteomic data are consistent with liter-
ature and point toward major changes in cell differentiation,
proliferation, development, growth factor signaling, learning,
DNA damage response, and phosphorylation upon TPP2 in-
hibition and knock down (20, 26, 68). The ERK2 signal trans-
duction affects at least transcription of genes involved in
proliferation and development as well as DNA repair and
cell-cycle-related genes. Additionally, our proteomic results
(Table I) indicate that TPP2 is upstream of processes involved
in learning, a biological process that has not been connected
to TPP2 before, probably because we are the first to use a
neuronal model system to study TPP2 function. Here, we have
linked TPP2 to synaptic transmission (Fig. 5) by showing that
TPP2 inhibition in hippocampal neurons led to an increase of
currents and consequently AMPA-type receptors at the post-
synaptic membrane (61), indicating a strengthening of syn-
FIG. 8. The relationship between
TPP2 and ERK1/2 phosphorylation.
TPP2 inhibition leads to a decrease of
active phosphorylated ERK1 and ERK2
via inducing an activation of (1) nuclear
phosphatases that dephosphorylate (-P)
pERKs and/or a decrease of (2) nuclear
kinase activity that targets ERK1 and
ERK2.
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apses. This finding implicates a role for TPP2 in neurological
processes that has never been described before.
The newly described involvement of TPP2 in neuronal func-
tion may relate to its influence on ERK1 and ERK2 phosphor-
ylation since in neurons the ERK2 pathway has been associ-
ated with synaptic plasticity and memory formation (35, 36).
The observed changes in synaptic plasticity can also be con-
nected to the moderate increase in SOX11 expression (56). It
has been shown that an increased expression of SOX11 (Fig.
4B) can activate the transcription of brain-derived neu-
rotrophic factor (BDNF), a protein modulating synaptic plas-
ticity related to memory, learning, and pain signaling (56, 73,
74). BDNF expression was found regulated by the neuronal
growth factor NGF, a signaling pathway that was influenced
by TPP2 (Supplemental Table III), and furthermore, BDNF
expression correlates with neurite outgrowth (75, 76). The
latter can be linked to the observed rapid increase of neurite
length in presence of TPP2 inhibition. The increase in neurite
length seems to be contradictory to the down-regulation of
ERK2 signaling downstream of neuronal growth factor recep-
tor. However, it has been shown that phosphatidylinositol
4-phosphate 3-kinase (PI3K) can promote neurite outgrowth
independent of ERK2 (77). The proteomic data show an in-
crease of the PI3K subunit PIK3C2A in all three proteomic
screens (Fig. 3 and Supplemental Table I), that could explain
the observed effect of TPP2 inhibition on neurite outgrowth
(Fig. 5).
In conclusion, using three independent approaches, includ-
ing the application of a novel potent TPP2 inhibitor, we dis-
covered a regulatory influence of TPP2 on the ERK2-mediated
signal transduction. We show that TPP2 inhibition down-
regulates the ERK2 pathway as it diminishes nuclear active
di-phosphorylated ERK1 and 2, most likely via activating its
dephosphorylation or inhibiting its phosphorylation in the nu-
cleus (Fig. 8). This finding can be connected to the described
influence of TPP2 on multitude biological processes, includ-
ing our second new finding, the strengthening of synapses by
TPP2 inhibition. Since ERK2 mediated signal transduction is
increased in one-third of all cancers (62), TPP2 might become
an interesting target for upstream control of the ERK pathway
in research fields like cancer and neurological or neurodegen-
erative diseases.
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